VivoSeq
Infectious Disease

Malaria

360

Pipeline Programs↗

53

Active Trials↗

46

Companies Involved↗

Malaria is a highly competitive landscape with 360 programs across 46 companies. The most active players are Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, Shanghai Wanxing Bio-Pharmaceutical Co. Ltd., Fraunhofer, Center for Molecular Biotechnology. 58 therapies are approved with 87 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

89/100

Pipeline Velocity

50/100

Mech. Concentration

10/100

Completion Rate

91/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

1 program

Phase 1S

Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.

1 program

Phase 1F

Fraunhofer, Center for Molecular Biotechnology

1 program

Phase 1A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Phase 1H

Hope Pharmaceuticals

1 program

Phase 1Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical46

Ustekinumab

Johnson & Johnson

Hydroxychloroquine Sulfate

Novartis

Plasmodium Falciparum Challenge

Radboud University Medical Center

Iron

Watson Pharmaceuticals

Antimalarials

University of Oxford

Phase 176

Rosiglitazone

Alnylam Pharmaceuticals

Zidovudine

Bp Consulting, Inc

MSP3-CRM-Vac4all/ Alhydrogel

Vac4All

Pfspz Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)

Pfspz Challenge

Merck & Co.

Phase 293

Epoetin Beta

Roche

Methylene Blue

Provepharm SAS

Pentoxifylline

Validus Pharmaceuticals

Levetiracetam

UCB

Engerix-B

GSK

Phase 387

Tafenoquine

Glaxo Dba Glaxosmithkline

Mannitol

B. Braun Medical Inc.

Yellow Fever Vaccine

Sanofi

Rabies Vaccine

Novartis

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved58

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cobicistat

Gilead

Acetaminophen

Kenvue Brands

Primaquine

Sanofi

Methotrexate

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

86%

Small molecule

296 of 344 classified programs — the dominant modality here.

14%ALL OTHERSVaccine4513%Protein / enzyme2<1%Monoclonal antibody1<1%

Small molecule leads; the ring shows all 344 classified programs, each share of the total. Modality classified for 99% of 480 pipeline programs.

Analysis

Trial Status

560

clinical trials

Completed422 · 75%
Unknown status45 · 8%
Terminated24 · 4%
Recruiting20 · 4%
Active, not recruiting20 · 4%
Not yet recruiting12 · 2%
Other17 · 3%

Clinical Trials

Trial Activity

560 trials

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Recruiting·NNoguchi Memorial Institute for Medical Research·N/A·NCT07389057·9,000 enrolled
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
Recruiting·UUniversity of Oxford·Phase 1·NCT06958198·56 enrolled
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
Recruiting·GSK logoGSK·Phase 3·NCT06666491·300 enrolled
Infant Malaria Vaccine Schedule Optimization
Recruiting·PPATH·Phase 2·NCT06879327·1,200 enrolled
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
Recruiting·GSK logoGSK·Phase 2·NCT07036159·238 enrolled
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
Recruiting·IInternational Vaccine Institute·N/A·NCT07416461·10,000 enrolled
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
Recruiting·MMenzies School of Health Research·Phase 4·NCT07468513·100 enrolled
Seasonal R21 Mass Vaccination for Malaria Elimination
Recruiting·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT06578572·16,200 enrolled
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
Recruiting·UUniversity of Oxford·Phase 3·NCT05951595·1,680 enrolled
OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
Recruiting·YYale University·Phase 4·NCT06967519·380 enrolled
FocaL Mass Drug Administration for Vivax Malaria Elimination
Recruiting·UUniversity of California, San Francisco·Phase 3·NCT05690841·7,530 enrolled
Evaluation of Artesunate in Infants Being Treated for Severe Malaria
Recruiting·AAmivas Inc.·N/A·NCT06555809·15 enrolled
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Recruiting·MMenzies School of Health Research·Phase 3·NCT06148792·1,090 enrolled
Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge
Recruiting·LLiverpool School of Tropical Medicine·Phase 3·NCT07082205·398 enrolled
Safety of Antimalarials in the FIRst trimEster
Recruiting·LLiverpool School of Tropical Medicine·Phase 3·NCT06962319·1,510 enrolled
Page 1 of 38

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)